A daily automated scan watches the feeds; nothing lands here until it's verified against a primary source. Every entry links the coverage and the eDietAdvice page it changes.
The complaint targets sharing sensitive health data with ad platforms and ROSCA billing/cancellation practices — context for anyone weighing the $149/month membership model.
The Hims dossier →PCAC voted to recommend BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for the 503A Bulks List on narrow margins (BPC-157 8–6); DSIP was voted down. FDA staff had recommended against inclusion, and the committee is advisory — the FDA's final call is still pending.
Our Legal-Status Tracker, updated →Participating Part D plans now cover Wegovy (pen and pill), Foundayo, and the Zepbound KwikPen at a flat $50 monthly copay through 2027 — below every cash price we track.
How the Bridge actually works →The proposed 503B Bulks List exclusion would close the mass-compounding era for good. Patient-specific 503A compounding continues — the legal market our index tracks at $139–$297 all-in.
The surviving market, explained →The most-watched peptide of the reclassification clears its first regulatory hurdle. Category 2 removal is separate from 503A compounding eligibility — two different tracks.
The two-track explainer →Lilly's once-daily oral launched via LillyDirect at $149–$349/month by dose, with promo tiers through 2026.
Every Foundayo price →The settlement ended the $49/day compounded oral semaglutide era at Hims, which now sells brand meds at manufacturer-matching prices plus its $149/month membership.
What the membership actually costs →The reversal of the 2023 restrictions began here. The FDA's formal updated list remains unpublished; every row of our tracker updates the day it drops.
The Legal-Status Tracker →The government site displays the manufacturers' lowest DTC prices and links out to NovoCare and LillyDirect. For cash buyers it changes almost nothing versus going direct.
The direct prices it points to →The first oral GLP-1 for weight loss, launched January 2026 at $149–$299/month by dose through NovoCare and retail cash programs.
Wegovy prices by channel →The ED telehealth pioneer survives under new ownership — still the only channel we track with an explicit one-time consult fee ($25, covers 12 refills) instead of a subscription.
The ED true-cost tables →The teledermatology brand closed and subscriptions were canceled — but stale affiliate listings for it still float around the internet. It stays in our records as a dead channel.
The telederm market, priced →All tracked news → · Fed by a daily automated scan; entries publish only after primary-source verification.